{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T10:38:02Z","timestamp":1784371082538,"version":"3.55.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,4,22]],"date-time":"2024-04-22T00:00:00Z","timestamp":1713744000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,22]],"date-time":"2024-04-22T00:00:00Z","timestamp":1713744000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005788","name":"Medical University of Vienna","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005788","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiologie"],"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:sec>\n                <jats:title>Hintergrund<\/jats:title>\n                <jats:p>Gut differenzierte neuroendokrine Tumoren (NET) sind seltene Malignome, die klinisch sehr heterogen sind. Entsprechend ist auch ihre Behandlung komplex und von diversen Faktoren abh\u00e4ngig. Mit den heute verf\u00fcgbaren Therapien ist die Prognose oft g\u00fcnstig.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Ziel der Arbeit<\/jats:title>\n                <jats:p>Dieser Artikel soll einen \u00dcberblick \u00fcber die aktuellen Therapiestrategien bei NET geben und dabei auf die wichtigsten NET-Lokalisationen eingehen.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methoden<\/jats:title>\n                <jats:p>Zu diesem Zweck wurden die aktuellen europ\u00e4ischen Leitlinien und die einschl\u00e4gige Literatur zur Behandlung von NET zusammengefasst.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Ergebnisse<\/jats:title>\n                <jats:p>Das Therapiespektrum ist ausgesprochen breit: Bei den NET des Magens\/Duodenums, der Appendix und des Rektums ist oft die endoskopische respektive chirurgische Entfernung ausreichend, und metastasierte Tumoren sind selten. NET des Pankreas, des D\u00fcnndarms und der Lunge sollen in fr\u00fchen Stadien auch einer potenziell kurativen Resektion zugef\u00fchrt werden. Im metastasierten Stadium haben lokale Therapiema\u00dfnahmen wie Chirurgie und Leber-Tumorembolisation ebenfalls einen Stellenwert. Zuletzt gab es viele Fortschritte hinsichtlich der medikament\u00f6sen Therapie, wobei insbesondere Somatostatin-Analoga (Octreotid und Lanreotid), ein mTOR-Inhibitor (Everolimus) und ein Tyrosinkinase-Inhibitor (Sunitinib) eingesetzt werden. Ferner stellt die Peptidrezeptor-Radionuklid-Therapie (PRRT) ein wichtiges Verfahren dar. Auch die klassische Chemotherapie ist in einigen F\u00e4llen indiziert.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Diskussion<\/jats:title>\n                <jats:p>Inzwischen gibt es viele effektive Therapien f\u00fcr NET. Es ist wichtig, im interdisziplin\u00e4ren Management f\u00fcr jeden Patienten und jede Patientin die richtige Therapie zum richtigen Zeitpunkt auszuw\u00e4hlen.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00117-024-01303-2","type":"journal-article","created":{"date-parts":[[2024,4,22]],"date-time":"2024-04-22T17:01:47Z","timestamp":1713805307000},"page":"568-574","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Aktuelle Entwicklungen in der Behandlung neuroendokriner Tumoren","Current developments in the treatment of neuroendocrine tumors"],"prefix":"10.1007","volume":"64","author":[{"given":"Barbara","family":"Kiesewetter-Wiederkehr","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Melhorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Scheuba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Raderer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,22]]},"reference":[{"key":"1303_CR1","doi-asserted-by":"publisher","first-page":"3507","DOI":"10.2147\/CMAR.S372776","volume":"14","author":"G Arrivi","year":"2022","unstructured":"Arrivi\u00a0G, Verrico\u00a0M, Roberto\u00a0M et\u00a0al (2022) Capecitabine and Temozolomide (CAPTEM) in Advanced Neuroendocrine Neoplasms (NENs): A\u00a0Systematic Review and Pooled Analysis. Cancer Manag Res 14:3507\u20133523","journal-title":"Cancer Manag Res"},{"key":"1303_CR2","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.annonc.2021.01.003","volume":"32","author":"E Baudin","year":"2021","unstructured":"Baudin\u00a0E, Caplin\u00a0M, Garcia-Carbonero\u00a0R et\u00a0al (2021) Lung and thymic carcinoids: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up(\u2606). Ann Oncol 32:439\u2013451","journal-title":"Ann Oncol"},{"key":"1303_CR3","doi-asserted-by":"publisher","first-page":"S906","DOI":"10.1016\/j.annonc.2021.08.178","volume":"32","author":"E Baudin","year":"2021","unstructured":"Baudin\u00a0E, Horsch\u00a0D, Singh\u00a0S et\u00a0al (2021) 1096O Lanreotide autogel\/depot (LAN) in patients with advanced bronchopulmonary (BP) neuroendocrine tumors (NETs): Results from the phase\u00a0III SPINET study. Ann Oncol 32:S906","journal-title":"Ann Oncol"},{"key":"1303_CR4","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1159\/000524988","volume":"112","author":"J Capdevila","year":"2022","unstructured":"Capdevila\u00a0J, Ducreux\u00a0M, Garc\u00eda Carbonero\u00a0R et\u00a0al (2022) Streptozotocin, 1982\u20132022: Forty Years from the FDA\u2019s Approval to Treat Pancreatic Neuroendocrine Tumors. Neuroendocrinology 112:1155\u20131167","journal-title":"Neuroendocrinology"},{"key":"1303_CR5","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1056\/NEJMoa1316158","volume":"371","author":"ME Caplin","year":"2014","unstructured":"Caplin\u00a0ME, Pavel\u00a0M, \u0106wik\u0142a\u00a0JB et\u00a0al (2014) Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N\u00a0Engl J Med 371:224\u2013233","journal-title":"N Engl J Med"},{"key":"1303_CR6","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1634\/theoncologist.2012-0263","volume":"18","author":"D Castellano","year":"2013","unstructured":"Castellano\u00a0D, Bajetta\u00a0E, Panneerselvam\u00a0A et\u00a0al (2013) Everolimus plus octreotide long-acting repeatable in patients with colorectal neuroendocrine tumors: a\u00a0subgroup analysis of the phase\u00a0III RADIANT-2\u00a0study. Oncologist 18:46\u201353","journal-title":"Oncologist"},{"key":"1303_CR7","doi-asserted-by":"publisher","first-page":"e13146","DOI":"10.1111\/jne.13146","volume":"34","author":"S Grozinsky-Glasberg","year":"2022","unstructured":"Grozinsky-Glasberg\u00a0S, Davar\u00a0J, Hofland\u00a0J et\u00a0al (2022) European Neuroendocrine Tumor Society (ENETS) 2022 Guidance Paper for Carcinoid Syndrome and Carcinoid Heart Disease. J\u00a0Neuroendocrinol 34:e13146","journal-title":"J Neuroendocrinol"},{"key":"1303_CR8","doi-asserted-by":"publisher","first-page":"e13318","DOI":"10.1111\/jne.13318","volume":"35","author":"J Hofland","year":"2023","unstructured":"Hofland\u00a0J, Falconi\u00a0M, Christ\u00a0E et\u00a0al (2023) European Neuroendocrine Tumor Society 2023 guidance paper for functioning pancreatic neuroendocrine tumour syndromes. J\u00a0Neuroendocrinol 35:e13318","journal-title":"J Neuroendocrinol"},{"key":"1303_CR9","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1210\/endrev\/bnz004","volume":"41","author":"J Hofland","year":"2020","unstructured":"Hofland\u00a0J, Kaltsas\u00a0G, De Herder\u00a0WW (2020) Advances in the Diagnosis and Management of Well-Differentiated Neuroendocrine Neoplasms. Endocr Rev 41:371\u2013403","journal-title":"Endocr Rev"},{"key":"1303_CR10","doi-asserted-by":"publisher","first-page":"e13332","DOI":"10.1111\/jne.13332","volume":"35","author":"G Kaltsas","year":"2023","unstructured":"Kaltsas\u00a0G, Walter\u00a0T, Knigge\u00a0U et\u00a0al (2023) European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for appendiceal neuroendocrine tumours (aNET). J\u00a0Neuroendocrinol 35:e13332","journal-title":"J Neuroendocrinol"},{"key":"1303_CR11","doi-asserted-by":"publisher","first-page":"e13343","DOI":"10.1111\/jne.13343","volume":"35","author":"B Kos-Kud\u0142a","year":"2023","unstructured":"Kos-Kud\u0142a\u00a0B, Casta\u00f1o\u00a0JP, Denecke\u00a0T et\u00a0al (2023) European Neuroendocrine Tumour Society (ENETS) 2023 guidance paper for nonfunctioning pancreatic neuroendocrine tumours. J\u00a0Neuroendocrinol 35:e13343","journal-title":"J Neuroendocrinol"},{"key":"1303_CR12","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1200\/JCO.22.01013","volume":"41","author":"PL Kunz","year":"2023","unstructured":"Kunz\u00a0PL, Graham\u00a0NT, Catalano\u00a0PJ et\u00a0al (2023) Randomized Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors (ECOG-ACRIN E2211). J\u00a0Clin Oncol 41:1359\u20131369","journal-title":"J Clin Oncol"},{"key":"1303_CR13","doi-asserted-by":"publisher","first-page":"e376","DOI":"10.1016\/j.cllc.2019.02.007","volume":"20","author":"BG Naraev","year":"2019","unstructured":"Naraev\u00a0BG, Ramirez\u00a0RA, Kendi\u00a0AT et\u00a0al (2019) Peptide Receptor Radionuclide Therapy for Patients With Advanced Lung Carcinoids. Clin Lung Cancer 20:e376\u2013e392","journal-title":"Clin Lung Cancer"},{"key":"1303_CR14","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/S1470-2045(22)00750-1","volume":"24","author":"C Nesti","year":"2023","unstructured":"Nesti\u00a0C, Br\u00e4utigam\u00a0K, Benavent\u00a0M et\u00a0al (2023) Hemicolectomy versus appendectomy for patients with appendiceal neuroendocrine tumours 1\u20132\u202fcm in size: a\u00a0retrospective, Europe-wide, pooled cohort study. Lancet Oncol 24:187\u2013194","journal-title":"Lancet Oncol"},{"key":"1303_CR15","doi-asserted-by":"publisher","first-page":"e13306","DOI":"10.1111\/jne.13306","volume":"35","author":"F Panzuto","year":"2023","unstructured":"Panzuto\u00a0F, Ramage\u00a0J, Pritchard\u00a0DM et\u00a0al (2023) European neuroendocrine tumor society (ENETS) 2023 guidance paper for gastroduodenal neuroendocrine tumours (NETs) G1-G3. J\u00a0Neuroendocrinol 35:e13306","journal-title":"J Neuroendocrinol"},{"key":"1303_CR16","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1159\/000443167","volume":"103","author":"M Pavel","year":"2016","unstructured":"Pavel\u00a0M, O\u2019toole\u00a0D, Costa\u00a0F et\u00a0al (2016) ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site. Neuroendocrinology 103:172\u2013185","journal-title":"Neuroendocrinology"},{"key":"1303_CR17","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.annonc.2020.03.304","volume":"31","author":"M Pavel","year":"2020","unstructured":"Pavel\u00a0M, \u00d6berg\u00a0K, Falconi\u00a0M et\u00a0al (2020) Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 31:844\u2013860","journal-title":"Ann Oncol"},{"key":"1303_CR18","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1056\/NEJMoa1003825","volume":"364","author":"E Raymond","year":"2011","unstructured":"Raymond\u00a0E, Dahan\u00a0L, Raoul\u00a0JL et\u00a0al (2011) Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N\u00a0Engl J Med 364:501\u2013513","journal-title":"N Engl J Med"},{"key":"1303_CR19","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s12022-022-09708-2","volume":"33","author":"G Rindi","year":"2022","unstructured":"Rindi\u00a0G, Mete\u00a0O, Uccella\u00a0S et\u00a0al (2022) Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms. Endocr Pathol 33:115\u2013154","journal-title":"Endocr Pathol"},{"key":"1303_CR20","doi-asserted-by":"publisher","first-page":"e13309","DOI":"10.1111\/jne.13309","volume":"35","author":"A Rinke","year":"2023","unstructured":"Rinke\u00a0A, Ambrosini\u00a0V, Dromain\u00a0C et\u00a0al (2023) European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for colorectal neuroendocrine tumours. J\u00a0Neuroendocrinol 35:e13309","journal-title":"J Neuroendocrinol"},{"key":"1303_CR21","doi-asserted-by":"publisher","first-page":"4656","DOI":"10.1200\/JCO.2009.22.8510","volume":"27","author":"A Rinke","year":"2009","unstructured":"Rinke\u00a0A, M\u00fcller\u00a0H\u2011H, Schade-Brittinger\u00a0C et\u00a0al (2009) Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A\u00a0Report From the PROMID Study Group. J\u00a0Clin Oncol 27:4656\u20134663","journal-title":"J Clin Oncol"},{"key":"1303_CR22","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1159\/000443612","volume":"104","author":"A Rinke","year":"2017","unstructured":"Rinke\u00a0A, Wittenberg\u00a0M, Schade-Brittinger\u00a0C et\u00a0al (2017) Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients with Metastatic Neuroendocrine Midgut Tumors (PROMID): Results of Long-Term Survival. Neuroendocrinology 104:26\u201332","journal-title":"Neuroendocrinology"},{"key":"1303_CR23","doi-asserted-by":"publisher","first-page":"S1412","DOI":"10.1016\/j.annonc.2022.08.044","volume":"33","author":"R Salazar","year":"2022","unstructured":"Salazar\u00a0R, Tafuto\u00a0S, Krogh\u00a0M et\u00a0al (2022) LBA45 Randomized open label phase\u00a0III study comparing the efficacy and safety of everolimus followed by chemotherapy (CT) with streptozotocin (STZ)-5FU upon progression or the reverse sequence, in advanced progressive panNETs: The SEQTOR study (GETNE 1206). Ann Oncol 33:S1412","journal-title":"Ann Oncol"},{"key":"1303_CR24","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1159\/000477585","volume":"106","author":"S Singh","year":"2018","unstructured":"Singh\u00a0S, Carnaghi\u00a0C, Buzzoni\u00a0R et\u00a0al (2018) Everolimus in neuroendocrine tumors of the gastrointestinal tract and unknown primary. Neuroendocrinology 106:211\u2013220","journal-title":"Neuroendocrinology"},{"key":"1303_CR25","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa1607427","volume":"376","author":"J Strosberg","year":"2017","unstructured":"Strosberg\u00a0J, El-Haddad\u00a0G, Wolin\u00a0E et\u00a0al (2017) Phase\u00a03 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors. N\u00a0Engl J Med 376:125\u2013135","journal-title":"N Engl J Med"},{"key":"1303_CR26","doi-asserted-by":"publisher","first-page":"4112","DOI":"10.1200\/JCO.2021.39.15_suppl.4112","volume":"39","author":"JR Strosberg","year":"2021","unstructured":"Strosberg\u00a0JR, Caplin\u00a0ME, Kunz\u00a0PL et\u00a0al (2021) Final overall survival in the phase\u00a03 NETTER-1\u00a0study of lutetium-177-DOTATATE in patients with midgut neuroendocrine tumors. J\u00a0Clin Oncol 39:4112\u20134112","journal-title":"J Clin Oncol"},{"key":"1303_CR27","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1159\/000493894","volume":"108","author":"C Toumpanakis","year":"2019","unstructured":"Toumpanakis\u00a0C, Fazio\u00a0N, Tiensuu Janson\u00a0E et\u00a0al (2019) Unmet Needs in Appendiceal Neuroendocrine Neoplasms. Neuroendocrinology 108:37\u201344","journal-title":"Neuroendocrinology"},{"key":"1303_CR28","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1016\/S0140-6736(15)00817-X","volume":"387","author":"JC Yao","year":"2016","unstructured":"Yao\u00a0JC, Fazio\u00a0N, Singh\u00a0S et\u00a0al (2016) Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a\u00a0randomised, placebo-controlled, phase\u00a03\u00a0study. Lancet 387:968\u2013977","journal-title":"Lancet"},{"key":"1303_CR29","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1200\/JCO.2007.15.4377","volume":"26","author":"JC Yao","year":"2008","unstructured":"Yao\u00a0JC, Hassan\u00a0M, Phan\u00a0A et\u00a0al (2008) One hundred years after \u201ccarcinoid\u201d: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J\u00a0Clin Oncol 26:3063\u20133072","journal-title":"J Clin Oncol"},{"key":"1303_CR30","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1056\/NEJMoa1009290","volume":"364","author":"JC Yao","year":"2011","unstructured":"Yao\u00a0JC, Shah\u00a0MH, Ito\u00a0T et\u00a0al (2011) Everolimus for Advanced Pancreatic Neuroendocrine Tumors. N\u00a0Engl J Med 364:514\u2013523","journal-title":"N Engl J Med"}],"container-title":["Die Radiologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00117-024-01303-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00117-024-01303-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00117-024-01303-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T12:03:02Z","timestamp":1730203382000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00117-024-01303-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,22]]},"references-count":30,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["1303"],"URL":"https:\/\/doi.org\/10.1007\/s00117-024-01303-2","relation":{},"ISSN":["2731-7048","2731-7056"],"issn-type":[{"value":"2731-7048","type":"print"},{"value":"2731-7056","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,22]]},"assertion":[{"value":"26 March 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"B.\u00a0Kiesewetter-Wiederkehr und M.\u00a0Raderer: Vortr\u00e4ge und Advisory Boards f\u00fcr IPSEN (nicht im Zusammenhang mit der vorliegenden Arbeit). P.\u00a0Melhorn und C. Scheuba geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}